StockData
Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd (RDY) stock

RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.98+0.19 (+1.28%)

Close on Nov 18, 2026Market cap $12.50BP/E 27.5Yield 0.57%

Dr Reddys Laboratories operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2026 it was ₹50.55B, down 29.6% from the year before. Over ten years it grew 5.5% a year on average. The highest annual figure on record is ₹71.84B in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2026Mar 31, 2026₹50.55B-29.6%
FY2025Mar 31, 2025₹71.84B+6.1%
FY2024Mar 31, 2024₹67.73B+18.5%
FY2023Mar 31, 2023₹57.14B+93.9%
FY2022Mar 31, 2022₹29.48B+21.4%
FY2021Mar 31, 2021₹24.28B+51.8%
FY2020Mar 31, 2020₹15.99B-23.4%
FY2019Mar 31, 2019₹20.89B+75.3%
FY2018Mar 31, 2018₹11.92B-11.7%
FY2017Mar 31, 2017₹13.50B-54.4%
FY2016Mar 31, 2016₹29.62B–

More Dr Reddys Laboratories figures

See a number that looks wrong?